International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors

Diabetes Care

Volumn 42, Issue 6, 2019, Pages 1147-1154

  Danne, Thomas ^a   Garg, Satish ^b   Peters, Anne L ^c   Buse, John B ^d   Mathieu, Chantal ^e   Pettus, Jeremy H ^f   Alexander, Charles M ^g   Battelino, Tadej ^h   Ampudia Blasco, F Javier ⁱ   Bode, Bruce W ^j   Cariou, Bertrand ^k   Close, Kelly L ^l   Dandona, Paresh ^m   Dutta, Sanjoy ⁿ   Ferrannini, Ele ^o   Fourlanos, Spiros ^p   Grunberger, George ^q   Heller, Simon R ^r   Henry, Robert R ^f   Kurian, Martin J ^s   Kushner, Jake A ^t   Oron, Tal ^u,v   Parkin, Christopher G ^w   Pieber, Thomas R ^x   Rodbard, Helena W ^y   Schatz, Desmond ^z   Skyler, Jay S ^aa   Tamborlane, William V ^ab   Yokote, Koutaro ^ac   Phillip, Moshe ^u,v   more..

^a Diabetes Centre for Children and Adolescents   (Germany)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g Alexander Assoc LLC   (United States)

^h UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j ATLANTA DIABETES ASSOCIATES   (United States)

^k NANTES UNIVERSITY HOSPITAL   (France)

^l diaTribe Foundation   (United States)

^m UNIVERSITY AT BUFFALO   (United States)

ⁿ JDRF International   (United States)

^o INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^p ROYAL MELBOURNE HOSPITAL   (Australia)

^q Grunberger Diabetes Institute   (United States)

^r UNIVERSITY OF SHEFFIELD   (United Kingdom)

^s Close Concerns   (United States)

^t McNair Medical Institute   (United States)

^u SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^v TEL AVIV UNIVERSITY   (Israel)

^w CGParkin Communications Inc   (United States)

^x MEDICAL UNIVERSITY OF GRAZ   (Austria)

^y Endocrine and Metabolic Consultants   (United States)

^z UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^aa UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^ab YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ac CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KETONE; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; ANTIDIABETIC AGENT; SODIUM;

ARTICLE; BLOOD PRESSURE; BODY WEIGHT; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MONITORING; PATIENT EDUCATION; PATIENT SELECTION; RISK ASSESSMENT; UNITED STATES; CONSENSUS; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK MANAGEMENT;

CONSENSUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; RISK MANAGEMENT; SODIUM; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85063888761     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-2316     Document Type: Article

References (45)

1. Cryer PE. Hypoglycemia: still the limiting factor in the glycemic management of diabetes. Endocr Pract 2008;14:750-756
2. Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulinomission inwomen with IDDM. Diabetes Care 1994;17:1178-1185
3. Polonsky WH, Anderson BJ, Lohrer PA, et al. Assessment of diabetes-related distress. Diabetes Care 1995;18:754-760
4. Peyrot M, Skovlund SE, Landgraf R. Epidemiology and correlates of weight worry in themultinational Diabetes Attitudes, Wishes and Needs study. Curr Med Res Opin 2009;25:1985-1993
5. U.S. Food and Drug Administration. FDAwarns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet], 15 May 2015. Available from https://www.fda.gov/downloads/drugs/drugSafety/ucm446954.pdf. Accessed 25 May 2018
6. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334
7. Zinman B, Wanner C, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
8. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657
9. Ferrannini E, Baldi S, Frascerra S, et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 2017;40: 771-776
10. Wiviott SD, Raz I, Bonaca MP, et al.; DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357
11. Lyons SK, Hermann JM, Miller KM, et al. Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,996 individuals in the prospective diabetes follow-up and T1D Exchange registries. Diabetes Care 2017;40: e139-e140
12. Astellas Pharma. Approval of Suglat tablets, selective SGLT2 inhibitor, for additional indication of type 1 diabetes mellitus and additional dosage and administration in Japan. Press release [Internet], 2018. Available from https://www.astellas.com/system/files/news/2018-12/181221-2-Eg-2.pdf. Accessed 24 December 2018
13. Dandona P, Mathieu C, Phillip M, et al.; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:864-876
14. Mathieu C, Dandona P, Gillard P, et al.; DEPICT-2 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial. Diabetes Care 2018;41:1938-1946
15. Dandona P, Mathieu C, Phillip M, et al.; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care 2018;41:2552-2559
16. McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 2018;61:2126-2133
17. Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE Trials. Diabetes Care 2018;41:2560-2569
18. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377:2337-2348
19. Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, Alba M. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care 2017; 40:171-180
20. Buse JB, Garg SK, Rosenstock J, et al. Fiftytwo-week efficacy and safety of sotagliflozin, a dual SGLT and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 diabetes (in Tandem1) (Abstract). Diabetes 2018;67(Suppl. 1): 212-OR
21. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015;38:1181-1188
22. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodiumglucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015;38:2258-2265
23. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-2852
24. Foster DW, McGarry JD. The regulation of ketogenesis. Ciba Found Symp 1982;87:120-131
25. Liljenquist JE, Bomboy JD, Lewis SB, et al. Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. J Clin Invest 1974; 53:190-197
26. Kibbey RG. SGLT-2 inhibition and glucagon: cause for alarm? Trends Endocrinol Metab 2015; 26:337-338
27. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-1642
28. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508
29. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512-517
30. Candelario N, Wykretowicz J. The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin. Oxf Med Case Rep 2016; 2016:144-146
31. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016;7:135-138
32. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-1693
33. Mosley JF II, Smith L, Everton E, Fellner C. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. P T 2015;40:451-462
34. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37:1480-1483
35. Laffel LM, Wentzell K, Loughlin C, Tovar A, Moltz K, Brink S. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial. Diabet Med 2006;23:278-284
36. Brooke J, Stiell M, Ojo O. Evaluation of the accuracy of capillary hydroxybutyrate measurement compared with othermeasurements in the diagnosis of diabetic ketoacidosis: a systematic review. Int J Environ Res Public Health 2016;13:E837
37. Misra S, Oliver NS. Utility of ketone measurement in the prevention, diagnosis and management of diabetic ketoacidosis. Diabet Med 2015;32:14-23
38. Klocker AA, Phelan H, Twigg SM, Craig ME. Blood b-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in type 1 diabetes: a systematic review. Diabet Med 2013;30:818-824
39. Plüddemann A, Heneghan C, Price CP, Wolstenholme J, Thompson M. Point-of-care blood test for ketones in patients with diabetes: primary care diagnostic technology update. Br J Gen Pract 2011;61:530-531
40. Sheikh-Ali M, Karon BS, Basu A, et al. Canserum b-hydroxybutyrate be used to diagnose diabetic ketoacidosis? Diabetes Care 2008;31:643-647
41. Dhatariya K. Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev Diabet Stud 2016;13:217-225
42. Garg SK, Peters AL, Buse JB, Danne T. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol. Diabetes Technol Ther 2018;20:571-575
43. Weinstock RS, Xing D, Maahs DM, et al.; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013;98:3411-3419
44. Albanese-O'Neill A, Wu M, Miller KM, Jacobsen L, Haller MJ, Schatz D; T1D Exchange Clinic Network. Poor adherence to ketone testing in patients with type 1 diabetes. Diabetes Care 2017;40:e38-e39
45. Walmart. Health/Diabetes Care/Ketone Test Strips [Internet]. Available from https://www.walmart.com/browse/health/ketone-test-strips/976760-1231757-3866822. Accessed 21 December 2018